Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Insulin Therapy in Hyperglycemic STEMI
NCT00670228Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Apr 2008
- Primary completion
- Nov 2009
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of insulin glulisine and insulin glargine in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by Sanofi. Primary endpoint: Infarct Size Absolute Change From Baseline at Day 60. Started Apr 2008; status: terminated.
02
Drugs
insulin glulisineinsulin glargine
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT00670228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00670228.